BRPI0516385B1 - Composto ou sal do mesmo contendo aminoácidos não naturais e polipeptídeos, métodos para produção e derivatização de um polipeptídeo - Google Patents
Composto ou sal do mesmo contendo aminoácidos não naturais e polipeptídeos, métodos para produção e derivatização de um polipeptídeo Download PDFInfo
- Publication number
- BRPI0516385B1 BRPI0516385B1 BRPI0516385-4A BRPI0516385A BRPI0516385B1 BR PI0516385 B1 BRPI0516385 B1 BR PI0516385B1 BR PI0516385 A BRPI0516385 A BR PI0516385A BR PI0516385 B1 BRPI0516385 B1 BR PI0516385B1
- Authority
- BR
- Brazil
- Prior art keywords
- substituted
- alkylene
- alkyl
- amino acid
- group
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
- C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
- C07C225/10—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/28—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
- C07C251/54—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
- C07C251/60—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/89—Benzo [c] furans; Hydrogenated benzo [c] furans with two oxygen atoms directly attached in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63841804P | 2004-12-22 | 2004-12-22 | |
US63852704P | 2004-12-22 | 2004-12-22 | |
US63919504P | 2004-12-22 | 2004-12-22 | |
US60/638,418 | 2004-12-22 | ||
US60/638,527 | 2004-12-22 | ||
US69630205P | 2005-07-01 | 2005-07-01 | |
US69606805P | 2005-07-01 | 2005-07-01 | |
US69621005P | 2005-07-01 | 2005-07-01 | |
US60/696,302 | 2005-07-01 | ||
US60/696,210 | 2005-07-01 | ||
US60/696,068 | 2005-07-01 | ||
PCT/US2005/046618 WO2006069246A2 (en) | 2004-12-22 | 2005-12-21 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0516385A BRPI0516385A (pt) | 2007-11-27 |
BRPI0516385B1 true BRPI0516385B1 (pt) | 2021-07-20 |
Family
ID=36602327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0516385-4A BRPI0516385B1 (pt) | 2004-12-22 | 2005-12-21 | Composto ou sal do mesmo contendo aminoácidos não naturais e polipeptídeos, métodos para produção e derivatização de um polipeptídeo |
Country Status (16)
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
US20220144872A1 (en) * | 2003-02-19 | 2022-05-12 | Panion & Bf Biotech Inc. | Pharmaceutical-Grade Ferric Organic Compounds, Uses Thereof and Methods of Making Same |
US20050287639A1 (en) | 2004-05-17 | 2005-12-29 | California Institute Of Technology | Methods of incorporating amino acid analogs into proteins |
EP1805217A2 (en) * | 2004-10-18 | 2007-07-11 | Novo Nordisk A/S | Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone |
WO2006069246A2 (en) * | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
CA2594580C (en) * | 2005-01-25 | 2013-09-24 | Wyeth Research Ireland Limited | Method for diafiltration |
US20070122408A1 (en) * | 2005-10-20 | 2007-05-31 | The Scripps Research Institute | Fc Labeling for Immunostaining and Immunotargeting |
WO2007056448A2 (en) * | 2005-11-08 | 2007-05-18 | Ambrx, Inc. | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
JP2009519942A (ja) * | 2005-12-14 | 2009-05-21 | アンブルックス,インコーポレイテッド | 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用 |
AU2007212021B2 (en) * | 2006-02-07 | 2013-06-06 | Takeda Pharmaceutical Company Limited | Stabilized compositions of proteins having a free thiol moiety |
WO2007103307A2 (en) | 2006-03-03 | 2007-09-13 | California Institute Of Technology | Site-specific incorporation of amino acids into molecules |
US7964181B2 (en) * | 2006-03-30 | 2011-06-21 | Palatin Technologies, Inc. | Amino acid surrogates for peptidic constructs |
US8580746B2 (en) * | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
US8114844B2 (en) * | 2006-03-30 | 2012-02-14 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptidomimetics |
JP5840345B2 (ja) | 2006-09-08 | 2016-01-06 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾ヒト血漿ポリペプチドまたは修飾ヒトFc足場タンパク質ならびにこれらの利用 |
WO2008049034A1 (en) * | 2006-10-17 | 2008-04-24 | Zymera, Inc. | System for assays of aminotranferase |
WO2008081024A1 (en) * | 2007-01-03 | 2008-07-10 | Novo Nordisk Health Care Ag | Subcutaneous administration of coagulation factor viia-related popypeptdes |
KR101476472B1 (ko) * | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 fgf-21 폴리펩티드 및 그 용도 |
NZ580686A (en) | 2007-05-02 | 2012-11-30 | Ambrx Inc | Modified interferon beta polypeptides and their uses |
US20110178029A1 (en) * | 2007-09-14 | 2011-07-21 | Ambrx, Inc. | Modified Human Apolipoprotein A-1 and Their Uses |
AU2008326324B9 (en) | 2007-11-20 | 2012-11-15 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
CN101939410A (zh) | 2007-12-11 | 2011-01-05 | 斯克利普斯研究院 | 甲基营养酵母菌巴斯德毕赤酵母中的体内非天然氨基酸表达 |
CN101959934B (zh) | 2008-01-11 | 2012-12-12 | 塞瑞纳治疗公司 | 聚噁唑啉共聚物的多官能形式和包含它的药物组合物 |
US8101706B2 (en) | 2008-01-11 | 2012-01-24 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
US9938333B2 (en) * | 2008-02-08 | 2018-04-10 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
DE102008002209A1 (de) * | 2008-06-04 | 2009-12-10 | Evonik Degussa Gmbh | Verfahren zur Aufreinigung von Erythropoietin |
ES2963062T3 (es) | 2008-07-23 | 2024-03-25 | Ambrx Inc | Polipéptidos G-CSF bovinos modificados y sus usos |
US20090197339A1 (en) * | 2008-12-10 | 2009-08-06 | The Scripps Research Institute | In vivo unnatural amino acid expression in the methylotrophic yeast pichia pastoris |
US8609383B2 (en) * | 2008-12-10 | 2013-12-17 | The Scripps Research Institute | Production of carrier-peptide conjugates using chemically reactive unnatural amino acids |
WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
EP2406276A4 (en) * | 2009-03-13 | 2012-12-05 | Aerovance Inc | METHOD OF RENATURING RECOMBINANT PROTEINS |
DE102009015347A1 (de) * | 2009-03-27 | 2010-09-30 | Man Nutzfahrzeuge Aktiengesellschaft | Dieselkraftstoff auf Ethanol-Basis |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
NZ598156A (en) | 2009-07-28 | 2014-06-27 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
WO2011044255A1 (en) * | 2009-10-06 | 2011-04-14 | The Ohio State University | Pyrrolysine analogs |
CN104017063A (zh) | 2009-12-21 | 2014-09-03 | Ambrx公司 | 经过修饰的猪促生长素多肽和其用途 |
CN107674121A (zh) | 2009-12-21 | 2018-02-09 | Ambrx 公司 | 经过修饰的牛促生长素多肽和其用途 |
US20110160143A1 (en) * | 2009-12-28 | 2011-06-30 | Perricone Nicholas V | Topical Acyl Glutathione Psoriasis Compositions |
EP2528615B1 (en) | 2010-01-27 | 2020-05-13 | Massachusetts Institute of Technology | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
JP5794558B2 (ja) * | 2010-03-24 | 2015-10-14 | 国立研究開発法人産業技術総合研究所 | 改変された致死遺伝子及び該遺伝子を含むベクター |
FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
EP2605789B1 (en) | 2010-08-17 | 2019-06-05 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
PL2654794T3 (pl) | 2010-12-22 | 2020-07-27 | Baxalta GmbH | Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem |
EP2663647A4 (en) | 2011-01-14 | 2015-08-19 | Redwood Bioscience Inc | POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD |
JP2013199466A (ja) * | 2012-02-24 | 2013-10-03 | Fujifilm Corp | リコピン含有組成物 |
US20150018530A1 (en) * | 2012-02-29 | 2015-01-15 | Ambrx, Inc. | Novel Prodrug Containing Molecule Compositions and Their Uses |
AU2013225816B2 (en) | 2012-03-02 | 2017-10-26 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Type III Gaucher Disease |
CN109265541A (zh) | 2012-05-10 | 2019-01-25 | 麻省理工学院 | 流感中和药剂 |
JP6425650B2 (ja) * | 2012-06-07 | 2018-11-21 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 前立腺特異的膜抗原抗体薬物複合体 |
US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
SG11201408494UA (en) * | 2012-06-19 | 2015-02-27 | Ambrx Inc | Anti-cd70 antibody drug conjugates |
GB201211353D0 (en) | 2012-06-26 | 2012-08-08 | Cm Online Ltd | Interactive video |
EP2863955B1 (en) | 2012-06-26 | 2016-11-23 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
SI3584255T1 (sl) | 2012-08-31 | 2022-05-31 | Sutro Biopharma, Inc | Modificirane aminokisline, ki vsebujejo azido skupino |
CN103933575B (zh) | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
EP2976362B1 (en) | 2013-03-19 | 2019-10-23 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
ES2658039T3 (es) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
KR20240024362A (ko) | 2014-10-24 | 2024-02-23 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
WO2016069726A1 (en) * | 2014-10-28 | 2016-05-06 | President And Fellows Of Harvard College | Methods of making polypeptides with non-standard amino acids using genomically recoded organisms |
WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
WO2016090157A1 (en) | 2014-12-04 | 2016-06-09 | Celgene Corporation | Biomolecule conjugates |
AU2016240847B2 (en) * | 2015-03-31 | 2021-07-29 | Eiken Kagaku Kabushiki Kaisha | Preservative solution for heme protein, and method for stabilizing heme protein |
JP2018512856A (ja) | 2015-04-17 | 2018-05-24 | アルパイン イミューン サイエンシズ インコーポレイテッド | 調整可能な親和性を有する免疫調節タンパク質 |
CN113350518A (zh) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
CA3011455A1 (en) | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
US11884612B2 (en) | 2016-03-16 | 2024-01-30 | The Regents Of The University Of California | Covalent peptide binders |
JP2019515677A (ja) | 2016-04-26 | 2019-06-13 | アール.ピー.シェーラー テクノロジーズ エルエルシー | 抗体複合体ならびにそれを作製および使用する方法 |
JP7138350B2 (ja) | 2016-11-14 | 2022-09-16 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | 共役連結体、該連結体を含有する細胞結合分子-薬物共役体、並びに該共役体及び連結体の使用及び製造方法 |
MX2019008449A (es) | 2017-02-08 | 2019-09-09 | Bristol Myers Squibb Co | Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos. |
CN110869044A (zh) | 2017-02-22 | 2020-03-06 | 倍奥英赛普特有限责任公司 | 肽和用肽治疗营养不良相关病症的方法 |
WO2018200381A1 (en) | 2017-04-25 | 2018-11-01 | Temple Otorongo Llc | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions |
AU2017422458B2 (en) * | 2017-07-05 | 2021-07-15 | Biocells (Beijing) Biotech Co., Ltd. | Polypeptide pharmaceutically acceptable salt et use thereof |
CA3071012A1 (en) | 2017-07-17 | 2019-01-24 | Bioincept, Llc | Peptides and methods of transplantation and restorative organ function |
US20210002325A1 (en) * | 2018-03-08 | 2021-01-07 | The Regents Of The University Of California | Bioreactive compositions and methods of use thereof |
CN108538399A (zh) * | 2018-03-22 | 2018-09-14 | 复旦大学 | 一种磁共振肝癌疗效评估方法和系统 |
AU2019246390A1 (en) | 2018-03-28 | 2020-08-06 | Ascendis Pharma A/S | Conjugates |
BR112020019639A2 (pt) | 2018-03-28 | 2021-01-05 | Ascendis Pharma Oncology Division A/S | Conjugados de il-2 |
CN110760306B (zh) * | 2018-07-27 | 2021-11-23 | Tcl科技集团股份有限公司 | 一种量子点的提纯方法 |
CA3110647A1 (en) | 2018-08-28 | 2020-03-05 | Ambrx, Inc. | Anti-cd3 antibody folate bioconjugates and their uses |
WO2020051331A1 (en) * | 2018-09-07 | 2020-03-12 | Medimmune, Llc | Methods of cell selection |
SG11202102427XA (en) | 2018-09-11 | 2021-04-29 | Ambrx Inc | Interleukin-2 polypeptide conjugates and their uses |
EP3867265A1 (en) | 2018-10-19 | 2021-08-25 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
JP2022520792A (ja) | 2019-02-12 | 2022-04-01 | アンブルックス,インコーポレイテッド | 抗体-tlrアゴニストコンジュゲートを含有する組成物、その方法、及び使用 |
CN113710686A (zh) | 2019-02-19 | 2021-11-26 | 阿尔缇玛基因组学公司 | 用于光学检测和测序的接头和方法 |
US20230025327A1 (en) | 2019-06-29 | 2023-01-26 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of tubulysin derivatives and cell binding molecules and methods of making |
CN113179631A (zh) * | 2019-11-25 | 2021-07-27 | 中国科学院理化技术研究所杭州研究院 | 通过临近使能反应疗法开发的共价蛋白质药物 |
US11807851B1 (en) | 2020-02-18 | 2023-11-07 | Ultima Genomics, Inc. | Modified polynucleotides and uses thereof |
WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
IL296099A (en) | 2020-03-11 | 2022-11-01 | Ambrx Inc | Interleukin-2 polypeptide conjugates and methods of using them |
JPWO2021215428A1 (US20060217532A1-20060928-C00093.png) * | 2020-04-22 | 2021-10-28 | ||
CN112028987B (zh) * | 2020-06-01 | 2021-07-30 | 广东圣赛生物科技有限公司 | 一种结合免疫抑制分子pd-l1的蛋白药物 |
CN116133676A (zh) | 2020-06-03 | 2023-05-16 | 阿森迪斯药物肿瘤股份有限公司 | Il-2序列及其用途 |
EP4199969A1 (en) * | 2020-08-18 | 2023-06-28 | Ultima Genomics, Inc. | Reagents for labeling biomolecules |
WO2022040596A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
CN114573714B (zh) * | 2021-03-15 | 2023-03-31 | 北京大学 | 用于靶分子修饰的缀合物及其制备方法 |
IL307282A (en) | 2021-04-03 | 2023-11-01 | Ambrx Inc | Antidote conjugates against HER2 and their applications |
WO2022232377A2 (en) * | 2021-04-28 | 2022-11-03 | The Regents Of The University Of California | Bioreactive proteins containing unnatural amino acids |
WO2023281485A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
US20230181754A1 (en) | 2021-07-09 | 2023-06-15 | Bright Peak Therapeutics Ag | Modified checkpoint inhibitors and uses thereof |
KR20240041379A (ko) | 2021-07-09 | 2024-03-29 | 브라이트 피크 테라퓨틱스 아게 | Il-2에 접합된 체크포인트 억제제 및 이의 용도 |
WO2023281482A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Cd20-targeted il-2 and its uses |
KR20240040134A (ko) | 2021-07-09 | 2024-03-27 | 브라이트 피크 테라퓨틱스 아게 | 항체 접합체 및 이의 제조 |
WO2023161857A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Bifunctional cytokine compositions |
WO2023161854A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
KR102526689B1 (ko) * | 2022-11-24 | 2023-04-28 | 주식회사 리얼이펙트 | 양친매성 항균펩타이드인 알루미늄 팔미토일다이펩타이드-4를 포함하는 액정수화 화장료 조성물 |
KR102524528B1 (ko) * | 2022-11-24 | 2023-04-21 | 주식회사 리얼이펙트 | 양친매성 항균펩타이드인 알루미늄 팔미토일다이펩타이드의 제조방법 |
Family Cites Families (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US644281A (en) * | 1899-12-01 | 1900-02-27 | Samuel Crump | Process of drying and varnishing prints. |
US3849576A (en) * | 1964-01-29 | 1974-11-19 | Oreal | Process and cosmetic compositions for the treatment of skin and scalp |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
GB1366554A (en) * | 1972-03-06 | 1974-09-11 | Science Union & Cie | Phenylalanine derivatives and a process for their preparation |
US4272432A (en) * | 1974-11-13 | 1981-06-09 | American Home Products Corporation | Claudogenic-interceptive nonapeptide |
ZA783356B (en) * | 1977-07-21 | 1979-06-27 | Merrell Toraude & Co | A-halomethyl amino acid derivatives |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
DE3043159C2 (de) * | 1980-11-15 | 1982-12-09 | Degussa Ag, 6000 Frankfurt | Cyclische Acetale des Glutaminsäure-γ-semialdehyds, Verfahren zu deren Herstellung und ihre Verwendung |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
JPS57206622A (en) | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4512922A (en) | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511502A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4820352A (en) | 1983-01-10 | 1989-04-11 | Bausch & Lomb Incorporated | Cleaning and conditioning solutions for contact lenses and methods of use |
US5089398A (en) | 1983-02-22 | 1992-02-18 | Chiron Corporation | Enhanced yeast transcription employing hybrid GAPDH promoter region constructs |
CA1341302C (en) | 1983-02-22 | 2001-10-09 | Rae Lyn Burke | Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein |
US4876197A (en) | 1983-02-22 | 1989-10-24 | Chiron Corporation | Eukaryotic regulatable transcription |
JPS59166086A (ja) | 1983-03-09 | 1984-09-19 | Teruhiko Beppu | 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法 |
ATE78293T1 (de) | 1983-05-27 | 1992-08-15 | Texas A & M Univ Sys | Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors. |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4689406A (en) | 1983-08-10 | 1987-08-25 | Amgen | Enhancement of microbial expression of polypeptides |
DE3486459D1 (de) | 1983-09-26 | 1997-12-11 | Udo Dr Med Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
DK518384A (da) | 1984-01-31 | 1985-07-01 | Idaho Res Found | Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse |
US4880734A (en) | 1984-05-11 | 1989-11-14 | Chiron Corporation | Eukaryotic regulatable transcription |
EP0164556B1 (en) | 1984-05-11 | 1994-03-02 | Chiron Corporation | Enhanced yeast transcription employing hybrid promoter region constructs |
US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4738921A (en) | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
US4837148A (en) | 1984-10-30 | 1989-06-06 | Phillips Petroleum Company | Autonomous replication sequences for yeast strains of the genus pichia |
EP0188256B1 (en) | 1985-01-14 | 1991-08-21 | NeoRx | Metal radionuclide labeled proteins for diagnosis and therapy |
JPS61243018A (ja) * | 1985-04-18 | 1986-10-29 | Taisho Pharmaceut Co Ltd | 真菌症治療剤 |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US5186933A (en) | 1986-12-30 | 1993-02-16 | Baylor College Of Medicine | Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system |
EP0349594A4 (en) | 1987-03-16 | 1990-09-26 | American Biogenetic Sciences, Inc. | Recombinant baculovirus occlusion bodies in vaccines and biological insecticides |
DK175243B1 (da) | 1987-03-23 | 2004-07-19 | Zymogenetics Inc | Ekspressionsvektor, der er i stand til at styre ekspression af heterologe gener eller cDNA i gær, gærværtscelle samt fremgangsmåde til öget produktion af proteiner i gærværtsceller |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
AU2136788A (en) | 1987-07-24 | 1989-03-01 | Cetus Corporation | Production of ricin toxins in a baculovirus-insect cell expression system |
CA1317244C (en) | 1987-07-24 | 1993-05-04 | Ernest Seigo Kawasaki | Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
CN1074422C (zh) | 1987-11-18 | 2001-11-07 | 希龙股份有限公司 | 制备含有hcv表位的分离多肽的方法 |
CA1340772C (en) | 1987-12-30 | 1999-09-28 | Patricia Tekamp-Olson | Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences |
JP2801322B2 (ja) | 1988-01-13 | 1998-09-21 | インスティチュート・パスツール | 溶血性リステリア属に特異的なdnaプローブ |
CA1324969C (en) | 1988-05-06 | 1993-12-07 | Jeffrey R. Shuster | High level expression of proteins in yeast |
US5674706A (en) | 1988-05-06 | 1997-10-07 | Chiron Corporation | High level expression of proteins in yeast |
FR2631974B1 (fr) | 1988-05-31 | 1992-12-11 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes |
AU4197389A (en) | 1988-08-05 | 1990-03-05 | Mount Sinai School Of Medicine Of The City University Of New York, The | In vivo infection of live insects with a recombinant baculovirus |
GB8819453D0 (en) | 1988-08-16 | 1988-09-21 | Roy P | Production of bluetongue virus non-structural proteins using baculovirus expression vector |
NZ230425A (en) | 1988-09-02 | 1992-07-28 | Molecular Eng Ass | Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector |
WO1990005785A1 (en) | 1988-11-18 | 1990-05-31 | The Regents Of The University Of California | Method for site-specifically incorporating unnatural amino acids into proteins |
WO1990010078A1 (en) | 1989-02-23 | 1990-09-07 | University Of Ottawa | Improved baculovirus expression system capable of producing foreign gene proteins at high levels |
CA2045614C (en) | 1989-02-24 | 1997-09-30 | James W. Bacus | Method and apparatus for determining a proliferation index of a cell sample |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
ATE300519T1 (de) | 1989-04-19 | 2005-08-15 | Enzon Inc | Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten |
JPH04501065A (ja) | 1989-05-17 | 1992-02-27 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション インコーポレイテッド | 改良されたバキュロウイルス発現ベクター |
FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
US5312808A (en) | 1989-11-22 | 1994-05-17 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
US5364840A (en) * | 1989-12-05 | 1994-11-15 | Vical, Inc. | Synthetic calcitonin peptides |
US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
CA2018801C (en) | 1990-06-12 | 2000-08-22 | Pierre Louis Beaulieu | Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus |
FR2664905B1 (fr) | 1990-07-18 | 1994-08-12 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus. |
WO1992001800A1 (en) | 1990-07-20 | 1992-02-06 | Chiron Corporation | Method for integrative transformation of yeast using dispersed repetitive elements |
FR2665923B1 (fr) | 1990-08-14 | 1993-01-22 | Arbona Jean | Unite de soins modulaire. |
JPH06500470A (ja) | 1990-09-04 | 1994-01-20 | メルク エンド カンパニー インコーポレーテッド | メチロトローフ酵母細胞におけるインスリン様成長因子の産生 |
IL99537A (en) * | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical preparations containing them |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5231178A (en) | 1991-01-16 | 1993-07-27 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Method for the purification of intact, correctly-folded insulin-like growth factor-1 |
WO1992016619A1 (en) | 1991-03-19 | 1992-10-01 | Us Army | Expression of influenza nucleoprotein antigens in baculovirus |
US6013433A (en) | 1991-04-26 | 2000-01-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
US5290686A (en) | 1991-07-31 | 1994-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | Expression of influenza a M2 protein in baculovirus |
IT1260468B (it) | 1992-01-29 | 1996-04-09 | Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole | |
DE69312700T2 (de) | 1992-04-14 | 1998-02-19 | Cornell Res Foundation Inc | Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung |
US5516657A (en) | 1992-05-11 | 1996-05-14 | Cambridge Biotech Corporation | Baculovirus vectors for expression of secretory and membrane-bound proteins |
AU5006993A (en) | 1992-08-21 | 1994-03-15 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
CA2110543A1 (en) * | 1992-12-09 | 1994-06-10 | David E. Wright | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof |
AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
US5464820A (en) * | 1993-06-22 | 1995-11-07 | The University Hospital | Specific inhibitors of tissue kallikrein |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
DE4335555A1 (de) | 1993-10-19 | 1995-04-20 | Basf Ag | Oximether und diese enthaltende Copolymerisate |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5605792A (en) | 1993-11-04 | 1997-02-25 | The Ohio State University Research Foundation | Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
FR2715664B1 (fr) | 1994-01-31 | 1996-04-12 | Proteine Performance Sa | Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux. |
JP3090586B2 (ja) | 1994-03-15 | 2000-09-25 | 片倉工業株式会社 | システインプロテアーゼ遺伝子欠損バキュロウイルスおよびその製造法並びにこれを利用する有用タンパク質の製造法 |
US6403375B1 (en) | 1994-08-24 | 2002-06-11 | Boyce Thompson Institute For Plant Research, Inc. | Establishment of Trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production |
US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
IL116085A (en) | 1994-12-16 | 1999-12-31 | Ortho Pharma Corp | Spray dried erythropoietin |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
EP0842275A1 (en) | 1995-02-17 | 1998-05-20 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | PRODUCTION OF BIOLOGICALLY ACTIVE RECOMBINANT BOVINE FOLLICLE STIMULATING HORMONE (REC bFSH) IN THE BACULOVIRUS EXPRESSION SYSTEM |
FR2732035B1 (fr) | 1995-03-23 | 1997-05-30 | Agronomique Inst Nat Rech | Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en oeuvre du dit procede |
US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
NZ308772A (en) | 1995-05-17 | 1999-04-29 | Du Pont | Recombinant baculovirus insecticides |
JPH09157578A (ja) * | 1995-12-08 | 1997-06-17 | Daikin Ind Ltd | 含フッ素塗料用材料およびそれを用いた被覆方法 |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
WO1997026332A1 (en) | 1996-01-17 | 1997-07-24 | Schering Corporation | Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists |
US5861279A (en) | 1996-01-17 | 1999-01-19 | Schering Corporation | Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists |
US5876916A (en) * | 1996-03-18 | 1999-03-02 | Case Western Reserve University | Pyruvate compounds and methods for use thereof |
SI0964702T1 (sl) | 1996-08-02 | 2007-02-28 | Ortho Mcneil Pharm Inc | Polipeptidi, ki imajo posamezen kovalentno vezan N-terminalni vodotopni polimer |
DE69738768D1 (de) | 1996-12-13 | 2008-07-24 | Novartis Vaccines & Diagnostic | Analyse und separation von pdgf-proteinen |
GB9703406D0 (en) | 1997-02-19 | 1997-04-09 | Chiron Spa | Expression of heterologous proteins |
WO1998055630A2 (en) | 1997-06-06 | 1998-12-10 | The Governors Of The University Of Alberta | Alpha-1,3-fucosyltransferase of helicobacter pylori |
US5965393A (en) | 1997-07-01 | 1999-10-12 | National Institute Of Immunology | Method for enhancing foreign gene expression in baculovirus expression vector system |
BR9812267B1 (pt) | 1997-07-14 | 2013-11-26 | Hormônio de crescimento recombinante. | |
GB9715660D0 (en) | 1997-07-25 | 1997-10-01 | Zeneca Ltd | Proteins |
US6492421B1 (en) | 1997-07-31 | 2002-12-10 | Athena Neurosciences, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
WO1999007862A1 (en) | 1997-08-05 | 1999-02-18 | Chiron Corporation | Novel pichia pastoris gene sequences and methods for their use |
DE19735593C2 (de) | 1997-08-15 | 1999-08-26 | Hepavec Ag Fuer Gentherapie | Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie |
US6090584A (en) | 1997-08-21 | 2000-07-18 | University Technologies International Inc. | Baculovirus artificial chromosomes and methods of use |
US6455550B1 (en) | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
EP1015576B1 (en) | 1997-09-16 | 2005-05-04 | Egea Biosciences, LLC | Method for the complete chemical synthesis and assembly of genes and genomes |
US6449281B1 (en) * | 1997-09-30 | 2002-09-10 | Intel Corporation | Interface control of communication between a control processor and a digital signal processor |
JPH11140076A (ja) * | 1997-11-04 | 1999-05-25 | Dai Ichi Pure Chem Co Ltd | N−アシル−α−アミノアジピン酸−γ−セミアルデヒドエチレンアセタール |
EP0924298A1 (en) | 1997-12-18 | 1999-06-23 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Protein expression in baculovirus vector expression systems |
WO1999045130A1 (en) | 1998-03-04 | 1999-09-10 | Onyx Pharmaceuticals, Inc. | Baculovirus expression system and method for high throughput expression of genetic material |
JP2002505338A (ja) | 1998-03-05 | 2002-02-19 | カイロン コーポレイション | 生物学的に活性な分子の血清半減期を増加するための方法 |
EE200000519A (et) * | 1998-03-11 | 2002-02-15 | G.D. Searle & Co. | Lämmastikoksiidi süntaasi inhibiitoritena toimivad halogeenitud amidinoaminohappederivaadid |
KR100264953B1 (ko) | 1998-04-03 | 2001-03-02 | 박현우 | 재조합 베큘로바이러스, 이의 제조방법 및 이를 포함하는 미생물 살충제 |
US6168932B1 (en) | 1998-07-13 | 2001-01-02 | Parker Hughes Institute | Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system |
US6245528B1 (en) | 1998-07-28 | 2001-06-12 | Academia Sinica | Latent baculovirus expression system |
US6368825B1 (en) | 1998-08-10 | 2002-04-09 | Academia Sinica | Baculovirus containing minimal CMV promoter |
AU6059699A (en) * | 1998-09-23 | 2000-04-10 | Regents Of The University Of California, The | Synthetic peptides, conjugation reagents and methods |
WO2000020032A1 (en) | 1998-10-06 | 2000-04-13 | Trustees Of Dartmouth College | RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY |
US6994986B2 (en) | 1999-03-17 | 2006-02-07 | The Board Of Trustees Of The Leland Stanford University | In vitro synthesis of polypeptides by optimizing amino acid metabolism |
US6342216B1 (en) | 1999-03-17 | 2002-01-29 | The Board Of Regents, The University Of Texas System | Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
EP1177311B1 (en) | 1999-03-17 | 2014-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel atp regeneration system |
US6337191B1 (en) * | 1999-03-22 | 2002-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Vitro protein synthesis using glycolytic intermediates as an energy source |
US6312725B1 (en) * | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
US6261805B1 (en) | 1999-07-15 | 2001-07-17 | Boyce Thompson Institute For Plant Research, Inc. | Sialyiation of N-linked glycoproteins in the baculovirus expression vector system |
WO2001027301A2 (en) | 1999-10-15 | 2001-04-19 | The Rockefeller University | System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae |
GB9929613D0 (en) * | 1999-12-15 | 2000-02-09 | Koninkl Philips Electronics Nv | Manufacture of semiconductor material and devices using that material |
SE0000055D0 (sv) * | 2000-01-10 | 2000-01-10 | Centaur Pharmaceuticals Inc | Novel process |
GB0012997D0 (en) | 2000-05-26 | 2000-07-19 | Eurogene Limited | Gene delivery |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
KR20030017569A (ko) * | 2000-06-28 | 2003-03-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 카르베딜올 |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
JP2002030098A (ja) | 2000-07-17 | 2002-01-29 | Institute Of Immunology Co Ltd | バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法 |
WO2002019963A2 (en) | 2000-09-08 | 2002-03-14 | Gryphon Therapeutics, Inc. | Synthetic erythropoiesis stimulating proteins |
DK2322631T3 (en) | 2001-04-19 | 2015-01-12 | Scripps Research Inst | Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar |
US6900218B2 (en) * | 2001-05-03 | 2005-05-31 | Galileo Pharmaceuticals, Inc. | Pyruvate derivatives |
US6608196B2 (en) * | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
GB0113657D0 (en) | 2001-06-05 | 2001-07-25 | Geneprot Inc | Improved native chemical ligation with three or more components |
US20030154058A1 (en) * | 2001-06-11 | 2003-08-14 | Keener Bryan F. | Methods and systems for validating translated geometry |
US20040138412A1 (en) | 2001-09-07 | 2004-07-15 | Paolo Botti | Extended native chemical ligation |
WO2003022261A1 (en) * | 2001-09-13 | 2003-03-20 | Miller Kenneth E | Method of alleviating pain |
JP4758608B2 (ja) | 2001-11-07 | 2011-08-31 | ネクター セラピューティックス | 分枝ポリマーおよびそれらの結合体 |
WO2003042235A2 (en) | 2001-11-14 | 2003-05-22 | Geneprot, Inc. | Extended native chemical ligation of three or more peptide fragments |
AU2002356990A1 (en) * | 2001-11-20 | 2003-06-10 | Pharmacia Corporation | Chemically-modified human growth hormone conjugates |
MXPA05003983A (es) | 2002-10-16 | 2005-06-22 | Scripps Research Inst | Incorporacion en sitio especifico de cetoaminoacidos en proteinas. |
EP1583816A4 (en) | 2002-12-22 | 2007-06-13 | Scripps Research Inst | PROTEIN NETWORKS |
MXPA05007163A (es) * | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Derivados polimericos de acido maleamico y sus bioconjugados. |
EP1590442A4 (en) * | 2003-02-07 | 2007-07-18 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
CN101223272B (zh) | 2003-04-17 | 2013-04-03 | 斯克利普斯研究院 | 扩展真核生物遗传密码 |
WO2005024005A1 (en) * | 2003-09-03 | 2005-03-17 | Intralytix, Inc. | Novel salmonella bacteriophage and uses thereof |
WO2006069246A2 (en) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
CA2594557C (en) * | 2004-12-22 | 2016-04-26 | Ambrx, Inc. | Modified human growth hormone |
JP4478883B2 (ja) * | 2005-03-25 | 2010-06-09 | ヤマハ株式会社 | 音楽再生装置およびプログラム |
DE102005036719A1 (de) * | 2005-07-28 | 2007-02-01 | Carl Zeiss Industrielle Messtechnik Gmbh | Verfahren zum Korrigieren von Interpolationsfehlern einer Maschine, insbesondere eines Koordinatenmessgerätes |
WO2007056448A2 (en) | 2005-11-08 | 2007-05-18 | Ambrx, Inc. | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
JP2009519942A (ja) | 2005-12-14 | 2009-05-21 | アンブルックス,インコーポレイテッド | 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用 |
KR20080081013A (ko) | 2005-12-30 | 2008-09-05 | 암브룩스, 인코포레이티드 | 비천연 아미노산 및 폴리펩티드를 함유하는 조성물, 그와관련된 방법 및 그 용도 |
US7760037B2 (en) * | 2007-03-28 | 2010-07-20 | Intel Corporation | Process, voltage, and temperature compensated clock generator |
US20090113333A1 (en) | 2007-10-26 | 2009-04-30 | Palm, Inc. | Extendable Toolbar for Navigation and Execution of Operational Functions |
-
2005
- 2005-12-21 WO PCT/US2005/046618 patent/WO2006069246A2/en active Application Filing
- 2005-12-21 SG SG200908439-3A patent/SG158148A1/en unknown
- 2005-12-21 EP EP05855215.9A patent/EP1828224B1/en active Active
- 2005-12-21 US US11/313,305 patent/US7638491B2/en active Active
- 2005-12-21 EP EP11177567.2A patent/EP2399893B1/en active Active
- 2005-12-21 US US11/313,306 patent/US7332571B2/en active Active
- 2005-12-21 BR BRPI0516385-4A patent/BRPI0516385B1/pt active IP Right Grant
- 2005-12-21 CA CA3005835A patent/CA3005835C/en active Active
- 2005-12-21 DK DK05855215.9T patent/DK1828224T3/en active
- 2005-12-21 SG SG200908440-1A patent/SG158149A1/en unknown
- 2005-12-21 CA CA2927595A patent/CA2927595C/en active Active
- 2005-12-21 GB GB0713066A patent/GB2438982A/en not_active Withdrawn
- 2005-12-21 KR KR1020077016540A patent/KR101423769B1/ko active IP Right Grant
- 2005-12-21 MX MX2007007590A patent/MX2007007590A/es active IP Right Grant
- 2005-12-21 CA CA2590590A patent/CA2590590C/en active Active
- 2005-12-21 SG SG200908678-6A patent/SG158186A1/en unknown
- 2005-12-21 NZ NZ555308A patent/NZ555308A/en unknown
- 2005-12-21 JP JP2007548475A patent/JP5425398B2/ja active Active
- 2005-12-21 CN CN201510093838.4A patent/CN104803865A/zh active Pending
- 2005-12-21 US US11/313,956 patent/US7385028B2/en active Active
- 2005-12-21 DK DK11177567.2T patent/DK2399893T3/en active
- 2005-12-21 AU AU2005319125A patent/AU2005319125A1/en not_active Abandoned
-
2007
- 2007-05-21 IL IL183346A patent/IL183346A/en active IP Right Grant
- 2007-10-16 US US11/873,347 patent/US7928163B2/en active Active
- 2007-10-17 US US11/874,060 patent/US7696312B2/en active Active
- 2007-10-17 US US11/874,094 patent/US20080177038A1/en not_active Abandoned
- 2007-10-18 US US11/874,486 patent/US20080213840A1/en not_active Abandoned
- 2007-10-26 US US11/925,699 patent/US20080268519A1/en not_active Abandoned
- 2007-10-26 US US11/925,662 patent/US20080268518A1/en not_active Abandoned
- 2007-10-26 US US11/925,743 patent/US20090111147A1/en not_active Abandoned
- 2007-12-07 US US11/952,975 patent/US8048988B2/en active Active
- 2007-12-07 US US11/952,960 patent/US8008456B2/en active Active
-
2008
- 2008-02-06 US US12/027,130 patent/US8263740B2/en active Active
- 2008-03-04 HK HK08102427.1A patent/HK1111702A1/zh unknown
-
2009
- 2009-11-05 US US12/613,423 patent/US8367612B2/en active Active
-
2010
- 2010-10-06 AU AU2010226982A patent/AU2010226982B2/en active Active
-
2011
- 2011-01-13 US US13/006,350 patent/US8859802B2/en active Active
- 2011-01-13 US US13/006,361 patent/US8791231B2/en active Active
- 2011-01-13 US US13/006,335 patent/US8809511B2/en active Active
- 2011-07-07 US US13/178,189 patent/US8476411B2/en active Active
-
2012
- 2012-06-20 US US13/528,723 patent/US8846876B2/en active Active
- 2012-07-03 IL IL220740A patent/IL220740A/en active IP Right Grant
-
2013
- 2013-08-01 IL IL227753A patent/IL227753A/en active IP Right Grant
-
2014
- 2014-05-29 US US14/290,797 patent/US9637441B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9637441B2 (en) | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | |
US20100098630A1 (en) | Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides | |
CN108047086B (zh) | 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 5A. ANUIDADES. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE DESPACHO 8.6 NA RPI 2175 DE 11/09/2012. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/12/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |